Mimedx Group Share Price (NASDAQ: MDXG)

$7.14

▲

-0.05

(-0.7%)

Live

Last updated on August 20, 2025 at 11:36 PM IST

$₹

Check the interactive Mimedx Group Stock chart to analyse performance

Mimedx Group stock performance

as on August 20, 2025 at 11:36 PM IST

Today's Low:$7.10
Today's High:$7.18
$7.14
0.56%
Downside
Day's Volatility :1.11%
Upside
0.56%
52 Weeks Low:$5.47
52 Weeks High:$10.14
$7.14
23.39%
Downside
52 Weeks Volatility :46.06%
Upside
29.59%

Mimedx Group Stock Returns

Period	Mimedx Group, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	4.35%	1.5%	0.0%
6 Months	-10.67%	-7.1%	0.0%
1 Year	11.46%	-11.4%	0.0%
3 Years	90.48%	2.9%	-9.6%

Mimedx Group, Inc. Key Stats

Check Mimedx Group key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$7.19
Open	$7.19
Today's High	$7.18
Today's Low	$7.1
Market Capitalization	$1.1B
Today's Volume	$584.7K
52 Week High	$10.14
52 Week Low	$5.47
Revenue TTM	$363.8M
EBITDA	$53.7M
Earnings Per Share (EPS)	$0.21
PE Ratio	34.24
Profit Margin	8.84%
Quarterly Earnings Growth YOY	-0.5%
Return On Equity TTM	16.61%

Stock Returns calculator for Mimedx Group Stock including INR - Dollar returns

The Mimedx Group stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Mimedx Group investment value today

Current value as on today

₹1,14,415

Returns

₹14,415

(+14.42%)

Returns from Mimedx Group Stock

₹10,526 (+10.53%)

Dollar Returns*

₹3,889 (+3.89%)

Indian investors sentiment towards Mimedx Group Stock

200%

Period: Jul 20, 2025 to Aug 19, 2025. Change in 30 Days versus previous period

Search interest for Mimedx Group Stock from India on INDmoney has increased by 200% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Mimedx Group, Inc.

Name
Holdings %
Name
Holdings %
Essex Woodlands Health Ventures
19.06%
BlackRock Inc
6.88%
Trigran Investments Inc
5.14%
Vanguard Group Inc
4.70%
Paradigm Capital Management, Inc.
3.17%
State Street Corp
2.34%

Analyst Recommendation on Mimedx Group Stock

Rating

Trend

Buy

90%Buy

9%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Mimedx Group(by analysts ranked 0 to 5 stars)

Mimedx Group Share Price Target

What analysts predicted

Upside of 70.87%

Target:

$12.20

Current:

$7.14

Mimedx Group share price target is $12.20, a slight Upside of 70.87% compared to current price of $7.14 as per analysts' prediction.

Mimedx Group Stock Insights

Price Movement
In the last 1 month, MDXG stock has moved up by 12.1%
Increasing Revenue
Revenue is up for the last 2 quarters, 88.20M → 98.60M (in $), with an average increase of 10.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 7.02M → 9.61M (in $), with an average increase of 27.0% per quarter
MDXG vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 63.3% return, outperforming this stock by 51.8%
MDXG vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.3% return, outperforming this stock by 28.6%
Price to Sales
ForMDXG every $1 of sales, investors are willing to pay $2.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $24.1 for every $1 of sales.

Mimedx Group, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$359.1M	↑ 0.0%
Net Income	$-30.0M	↑ 0.0%
Net Profit Margin	-8.35%	↑ 0.0%

	FY20	Y/Y Change
Revenue	$248.2M	↓ 30.88%
Net Income	$-49.3M	↑ 64.4%
Net Profit Margin	-19.85%	↓ 11.5%

	FY21	Y/Y Change
Revenue	$258.6M	↑ 4.18%
Net Income	$-10.3M	↓ 79.13%
Net Profit Margin	-3.98%	↑ 15.87%

	FY22	Y/Y Change
Revenue	$267.8M	↑ 3.57%
Net Income	$-30.2M	↑ 193.6%
Net Profit Margin	-11.27%	↓ 7.29%

	FY23	Y/Y Change
Revenue	$321.5M	↑ 20.03%
Net Income	$67.4M	↓ 323.33%
Net Profit Margin	20.98%	↑ 32.25%

	FY24	Y/Y Change
Revenue	$348.9M	↑ 8.52%
Net Income	$42.4M	↓ 37.1%
Net Profit Margin	12.16%	↓ 8.82%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$84.7M	↓ 2.44%
Net Income	$9.3M	↓ 85.23%
Net Profit Margin	10.93%	↓ 61.26%

	Q2 FY24	Q/Q Change
Revenue	$87.2M	↑ 2.95%
Net Income	$17.6M	↑ 90.31%
Net Profit Margin	20.21%	↑ 9.28%

	Q3 FY24	Q/Q Change
Revenue	$84.1M	↓ 3.61%
Net Income	$8.1M	↓ 54.07%
Net Profit Margin	9.63%	↓ 10.58%

	Q4 FY24	Q/Q Change
Revenue	$92.9M	↑ 10.53%
Net Income	$7.4M	↓ 8.12%
Net Profit Margin	8.01%	↓ 1.62%

	Q1 FY25	Q/Q Change
Revenue	$88.2M	↓ 5.06%
Net Income	$7.0M	↓ 5.58%
Net Profit Margin	7.96%	↓ 0.05%

	Q2 FY25	Q/Q Change
Revenue	$98.6M	↑ 11.79%
Net Income	$9.6M	↑ 36.95%
Net Profit Margin	9.75%	↑ 1.79%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$322.7M	↑ 0.0%

	FY20	Y/Y Change
Profit	$208.9M	↓ 35.27%

	FY21	Y/Y Change
Profit	$215.3M	↑ 3.08%

	FY22	Y/Y Change
Profit	$219.5M	↑ 1.95%

	FY23	Y/Y Change
Profit	$266.8M	↑ 21.55%

	FY24	Y/Y Change
Profit	$288.8M	↑ 8.23%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$71.5M	↓ 2.0%

	Q2 FY24	Q/Q Change
Profit	$72.2M	↑ 0.88%

	Q3 FY24	Q/Q Change
Profit	$68.7M	↓ 4.75%

	Q4 FY24	Q/Q Change
Profit	$76.0M	↑ 10.57%

	Q1 FY25	Q/Q Change
Profit	$71.6M	↓ 5.73%

	Q2 FY25	Q/Q Change
Profit	$79.9M	↑ 11.55%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$35.8M	↑ 0.0%
Investing Cash Flow	$-9.2M	↑ 0.0%
Financing Cash Flow	$-8.9M	↑ 0.0%

	FY20	Y/Y Change
Operating Cash Flow	$-39.4M	↓ 210.1%
Investing Cash Flow	$-4.6M	↓ 50.6%
Financing Cash Flow	$62.9M	↓ 803.59%

	FY21	Y/Y Change
Operating Cash Flow	$-2.0M	↓ 94.97%
Investing Cash Flow	$-3.4M	↓ 25.47%
Financing Cash Flow	$-3.4M	↓ 105.33%

	FY22	Y/Y Change
Operating Cash Flow	$-17.9M	↑ 802.77%
Investing Cash Flow	$-2.7M	↓ 21.65%
Financing Cash Flow	$-580.0K	↓ 82.7%

	FY23	Y/Y Change
Operating Cash Flow	$26.8M	↓ 249.64%
Investing Cash Flow	$-2.2M	↓ 18.98%
Financing Cash Flow	$-8.6M	↑ 1377.59%

	FY24	Y/Y Change
Operating Cash Flow	$66.2M	↑ 147.24%
Investing Cash Flow	$-9.6M	↑ 344.69%
Financing Cash Flow	$-34.2M	↑ 299.05%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$4.9M	↓ 52.45%
Investing Cash Flow	$-6.0M	↑ 1152.39%
Financing Cash Flow	$-32.4M	↑ 262.04%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$21.8M	↑ 347.28%
Investing Cash Flow	$-905.0K	↓ 84.98%
Financing Cash Flow	$-359.0K	↓ 98.89%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$19.6M	↓ 10.04%
Investing Cash Flow	$113.0K	↓ 112.49%
Financing Cash Flow	$27.0K	↓ 107.52%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$18.8M	↓ 4.29%
Investing Cash Flow	$-2.8M	↓ 2548.67%
Financing Cash Flow	$-400.0K	↓ 1581.48%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$5.3M	↓ 71.79%
Investing Cash Flow	$-406.0K	↓ 85.33%
Financing Cash Flow	$-2.9M	↑ 619.5%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$14.4M	↑ 172.11%
Investing Cash Flow	$-887.0K	↑ 118.47%
Financing Cash Flow	$-1.1M	↓ 61.99%

Mimedx Group Technicals Summary

Sell

Neutral

Buy

Mimedx Group is currently in a neutral trading position according to technical analysis indicators.

Mimedx Group, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Mimedx Group, Inc.	8.27%	-10.67%	11.46%	90.48%	-0.41%
Regeneron Pharmaceuticals, Inc.	4.65%	-16.73%	-52.11%	-6.73%	-5.71%
Beone Medicines Ltd	7.16%	32.17%	61.08%	80.84%	30.07%
Vertex Pharmaceuticals Incorporated	-14.79%	-17.19%	-19.84%	32.96%	44.01%
Alnylam Pharmaceuticals, Inc.	43.03%	83.01%	63.29%	110.39%	235.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Mimedx Group, Inc.	34.24	34.24	2.97	0.33	0.17	0.1	NA	1.46
Regeneron Pharmaceuticals, Inc.	14.47	14.47	1.18	39.36	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.73	27.73	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Mimedx Group, Inc.	Buy	$1.1B	-0.41%	34.24	8.84%
Regeneron Pharmaceuticals, Inc.	Buy	$60.8B	-5.71%	14.47	31.37%
Beone Medicines Ltd	NA	$39.3B	30.07%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.0B	44.01%	27.73	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.8B	235.62%	NA	-12.96%

About Mimedx Group, Inc.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Organization	Mimedx Group
Employees	837
CEO	Mr. Joseph H. Capper
Industry	Biotechnology

Key Management of Mimedx Group, Inc.

Name	Title
Mr. Joseph H. Capper	CEO & Director
Mr. Douglas C. Rice CPA	Chief Financial Officer
Ms. Ricci S. Whitlow	Executive VP & COO
Mr. William F. Hulse IV	General Counsel & Chief Administrative Officer
Ms. Kimberly Maersk-Moller	Chief Commercial Officer
Mr. Matthew M. Notarianni	Head of Investor Relations
Mr. Mark P. Graves	Senior VP & Chief Compliance Officer
Ms. Hilary Dixon	Vice President of Investor Relations & Corporate Strategic Communications
Ms. Kate Surdez	Chief Human Resources Officer
Dr. David H. Mason Jr., M.D.	Chief Medical Officer

Important FAQs about investing in MDXG Stock from India :

What is Mimedx Group share price today?

Mimedx Group share price today is $7.14 as on August 20, 2025 at 11:36 PM IST. Mimedx Group share today touched a day high of $7.18 and a low of $7.10.

What is the 52 week high and 52 week low for Mimedx Group share?

Mimedx Group share touched a 52 week high of $10.14 and a 52 week low of $5.47. Mimedx Group stock price today i.e. August 20, 2025 at 11:36 PM IST is trending at $7.14, lower by 29.59% versus the 52 week high.

How to invest in Mimedx Group Stock (MDXG) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Mimedx Group on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Mimedx Group Shares that will get you 0.2101 shares as per Mimedx Group share price of $7.14 per share as on August 20, 2025 at 11:36 PM IST.

What is the minimum amount required to buy Mimedx Group Stock (MDXG) from India?

Indian investors can start investing in Mimedx Group (MDXG) shares with as little as ₹87.0225 or $1 (as of August 20, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹870.22 in Mimedx Group stock (as per the Rupee-Dollar exchange rate as on August 20, 2025). Based on Mimedx Group share’s latest price of $7.14 as on August 20, 2025 at 11:36 PM IST, you will get 1.4006 shares of Mimedx Group. Learn more about fractional shares .

What are the returns that Mimedx Group has given to Indian investors in the last 5 years?

Mimedx Group stock has given -0.41% share price returns and 16.26% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?